# EDGAR Filing Document

**Accession Number:** 0001567892
**File Stem:** 0001628280-26-022200
**Filing Date:** 2026-3
**Character Count:** 68248
**Document Hash:** 6c4018e8bd2a074a8ac15f34efb070c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-022200.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001628280-26-022200

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260331

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Keenova Therapeutics plc
- **CENTRAL INDEX KEY:** 0001567892
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981088325
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35803
- **FILM NUMBER:** 26816790

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15
- **BUSINESS PHONE:** 353 1 6960000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mallinckrodt plc
- **DATE OF NAME CHANGE:** 20130125

?xml version='1.0' encoding='ASCII'? mnk-20260331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)** 

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 31, 2026

**Keenova Therapeutics plc** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Ireland** | **001-35803** | **98-1088325** |
| (State or other jurisdiction <br>of incorporation) | (Commission <br>File Number) | (IRS Employer<br> Identification No.) |

---

**College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland**

(Address of principal executive offices)

**+353 1 696 0000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On March 31, 2026, Keenova Therapeutics plc ("Keenova" or the "Company") announced its unaudited financial results for the three months ended December 31, 2025, as set forth in the attached Exhibit 99.1. Additionally, the Company is furnishing certain supplemental unaudited pro forma financial results for the fiscal year ended December 31, 2025, as set forth on the attached Exhibit 99.2.

As previously announced, following the Company's merger with Endo LP (formerly known as Endo, Inc., "Endo") in July 2025 (the "Business Combination") and spin-off of its combined generics and sterile injectables businesses in November 2025 (the "Spin-Off"), the Company is known as Keenova. Keenova's business strategy focuses on developing, manufacturing and commercializing branded therapeutics that address key areas of significant unmet need, including rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. Consistent with this strategy, and at the direction of its Board of Directors, Keenova continues to explore a variety of transactions, intended to maximize shareholder value, including potential acquisitions, divestitures, financings and other strategic transactions. In connection with this process, Keenova intends to exit from its remaining opioid business and is currently pursuing the divestiture of its Percocet business.

**2026 Financial Guidance**

For the full-year 2026, Keenova expects to deliver:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acthar Gel net sales growth rate in the mid-teens.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• XIAFLEX net sales growth rate in the mid- to high-single digits.<sup>(1)</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales of $1.94 billion to $2.00 billion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $730 million to $760 million.

<sup>(1)</sup> Compared to aggregate XIAFLEX net sales for fiscal year 2025, which is calculated based on Endo's XIAFLEX net sales of $299.7 million for the pre-merger portion of fiscal year 2025 and Keenova's XIAFLEX net sales of $246.6 million for the post-merger portion of fiscal year 2025, for a total of $546.3 million.

The above Adjusted EBITDA guidance incorporates anticipated merger synergies expected to be realized in 2026. The guidance for net sales and Adjusted EBITDA does not take into account any potential acquisition or divestiture activity, including the sale of the Percocet business, which is expected to generate approximately $65 million in net sales and approximately $64 million in Adjusted EBITDA for full-year 2026.

Adjusted EBITDA is a non-GAAP measure and should not be viewed as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Adjusted EBITDA represents net income or loss prepared in accordance with GAAP and adjusted for certain items that management believes are not reflective of the operational performance of the business. Adjustments to GAAP amounts include, as applicable to each measure, interest expense, net; income tax expense; depreciation and amortization; combination, integration, and other related expenses; restructuring charges, net; liabilities management and separation costs; gains/losses on debt extinguishment; gains/losses on divestitures; fresh-start inventory-related expenses; business combination inventory-related expense; share-based compensation; and other items identified by the Company.

The Company does not provide a comparable GAAP measure for its forward-looking non-GAAP guidance for Adjusted EBITDA or a reconciliation of such measure because the reconciling items described in the definition of Adjusted EBITDA above are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. The variability of such items may have a significant impact on our future GAAP results. Please see "Non-GAAP Financial Measure" included in Exhibit 99.1 for a more complete discussion of non-GAAP measures.

The information contained in this Item 2.02, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such a filing.

**Item 8.01 Other Events.**

**Delay in Filing of Form 10-K**

The Company will file a Form 12b-25 with the Securities and Exchange Commission on April 1, 2026, which will have the effect of extending the deadline for its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "2025 Form 10-K") until April 15, 2026. The Company requires additional time to complete certain analyses and disclosures to be included in the 2025 Form 10-K due to the complexity of the accounting related to the Business Combination and the Spin-Off, including updating purchase accounting and related valuations, the determination of discontinued operations presentation and related financial statement disclosures. The Company intends to file the 2025 Form 10-K on or prior to April 15, 2026.

------

**Potential Covenant Defaults**

The delay in timely filing the 2025 Form 10-K and the resulting delay in delivery of required audited annual financial statements will result in covenant defaults under certain of the Company's debt arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Credit Agreement, dated as of April 23, 2024 (as amended, modified or supplemented from time to time, the "Credit Agreement"), by and among Endo, as parent, Endo Finance Holdings LP (formerly known as Endo Finance Holdings, Inc.) ("Endo Borrower"), as borrower, the additional borrowers from time to time party thereto, the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent, collateral agent, issuing bank and swingline lender (the "Agent"), with respect to (i) a revolving credit facility with total commitments of $400.0 million with a maturity date of April 23, 2029, which revolving credit facility is undrawn (other than letters of credit with an aggregate face amount of $4.0 million as of December 31, 2025) and (ii) a term loan facility with a maturity date of April 23, 2031, with a current outstanding principal balance of $1,481.3 million as of December 31, 2025, requires the Company to deliver audited annual consolidated financial statements within 90 days after the end of each fiscal year. Because of the delay in filing the 2025 Form 10-K and resulting delay in delivering the audited annual financial statements, the Company could receive from the Agent notice of the occurrence of a default under the Credit Agreement. If the failure to deliver the audited annual financial statements continues for a period of 30 days after receipt of notice from the Agent (the "Credit Agreement Grace Period"), it will constitute an Event of Default (as that term is defined in the Credit Agreement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an Event of Default occurs under the Credit Agreement, the Agent or lenders holding a majority of the exposure thereunder may terminate the commitments thereunder to extend further credit and declare the loans thereunder to be immediately due and payable. Additionally, from the date that is three business days after the deadline for delivery of audited annual financial statements until three business days after the date audited annual financial statements are actually delivered, the applicable margin on term loans under the Credit Agreement will be increased by 25 basis points. Further, absence of a default is a condition to draws on the revolving credit facility under the Credit Agreement. Accordingly, until the Company cures the default by delivering the required audited annual financial statements, it will not be able to draw on the revolving credit facility.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company intends to file the 2025 Form 10-K and deliver the required audited annual financial statements prior to expiration of the Credit Agreement Grace Period, which will cure the default.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Indenture, dated April 23, 2024 (as amended, modified or supplemented from time to time, the "Indenture"), by and among Endo Borrower, as issuer, Endo, the subsidiary guarantors from time to time party thereto and Computershare Trust Company, National Association, as trustee and notes collateral agent (the "Trustee"), related to Endo Borrower's 8.50% Senior Secured Notes due April 2031 (the "Notes") with an outstanding principal balance of $1,000.0 million as of December 31, 2025, requires the Company to deliver audited annual consolidated financial statements within 90 days after the end of each fiscal year.

Because of the delay in filing the 2025 Form 10-K and resulting delay in delivering the audited annual financial statements, the Company could receive from the Trustee notice of the occurrence of a default under the Indenture. If the failure to deliver the audited annual financial statements continues for a period of 60 days after receipt of notice from the Trustee (the "Indenture Grace Period"), it will constitute an Event of Default (as that term is defined in the Indenture). During an Event of Default under the Indenture, either the Trustee or holders of at least 30% in aggregate principal amount of the outstanding Notes may declare the Notes to be immediately due and payable.

The Company intends to file the 2025 Form 10-K and deliver the required audited annual financial statements prior to expiration of the Indenture Grace Period, which will cure the default.

**Cautionary Note Regarding Forward-Looking Statements**

Statements in this Current Report on Form 8-K that are not strictly historical, including statements regarding the future financial condition and operating results of the Company and any other statements regarding events or developments Keenova believes or anticipates will or may occur in the future, may be "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements, including, among other things, the risk that the completion and filing of the 2025 Form 10-K will take longer than expected and any related consequences thereof, including triggering an event of default with respect to the Company's Credit Agreement and/or Indenture, which could result in substantially all of the Company's debt under the applicable agreement becoming immediately due and payable if the Company does not file the 2025 Form 10-K within the Credit Agreement Grace Period and the Indenture Grace Period, as applicable; the expected benefits and synergies of the Business Combination may not be fully realized in a timely manner, or at all; the Company's increased indebtedness as a result of the Business Combination and significant transaction costs related to the Business Combination; the expected growth opportunities, profit improvements, cost savings and other benefits as a result of the Spin-Off may not be fully realized in a timely manner, or at all; loss of the benefits of services provided by Par Health or certain of its subsidiaries; potential changes in the estimated fair value of the net assets acquired in the Business Combination; potential changes in the Company's business strategy and performance; exposure to global economic conditions and market uncertainty; the Company's substantial indebtedness and settlement obligation, its ability to generate sufficient cash to reduce its indebtedness and its potential need and ability to incur further indebtedness; the comparability of the Company's financial results to historical financial statements in light of its emergence from Chapter 11 bankruptcy proceedings in

------

2023, the divestiture of the Therakos business, the Business Combination and Spin-Off. The "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 27, 2024, its subsequent Quarterly Reports on Form 10-Q, its Registration Statement on Form S-4, as amended, filed with the Securities and Exchange Commission ("SEC") and other filings with the SEC, identify and describe in more detail the risks and uncertainties to which the Company's businesses are subject. There may be other risks and uncertainties that the Company is unable to predict at this time or that the Company currently does not expect to have a material adverse effect on its business. The forward-looking statements made herein speak only as of the date hereof and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information except as required by law. Given these uncertainties, one should not put undue reliance on any forward-looking statements.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d) *Exhibits*

---

| | |
|:---|:---|
| **Exhibit Number** | **Exhibit** |
| 99.1 | <u>[Fourth Quarter Financial Results.](a20251231keenovaex991q4202.htm)</u> |
| 99.2 | <u>[Supplemental Financial Information](a20251231keenovaex992q4202.htm)[.](a20251231keenovaex992q4202.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **KEENOVA THERAPEUTICS PLC** |
| | | | (registrant) |
| Date: | March 31, 2026 | By: | /s/ Christiana Stamoulis |
|  |  |  | Christiana Stamoulis |
|  |  |  | *President and Chief Financial Officer*<br>*(Principal Financial Officer)* |

---

## Exhibit 99.1

**Exhibit 99.1**

![logoa.jpg](logoa.jpg)

**<u>NOT</u> FOR IMMEDIATE RELEASE**

**Keenova Announces Unaudited Fourth Quarter 2025 Financial Results**

*Robust Fourth-Quarter Performance Driven by Strength in Acthar*<sup>®</sup> *Gel*<sup>1</sup> *and XIAFLEX*<sup>®2</sup>

*Financial and Operational Performance Exceeded Expectations as Company Completed Transition into Branded Therapeutics Company*

*Hammer Toe Trial Meets Primary Safety Endpoint and Secondary, Exploratory Efficacy Endpoints*

*Provides 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million*

*Conference Call and Webcast Today at 8:00 a.m. ET*

**Fourth Quarter 2025 Highlights**<sup>3</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Acthar Gel net sales of $205.6 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• XIAFLEX net sales of $156.5 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales from continuing operations of $543.0 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Loss from continuing operations expected to be between $105.0 million and $115.0 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA from continuing operations expected to be between $210.0 million and $220.0 million

**DUBLIN, March 31, 2026** – Keenova Therapeutics plc ("Keenova" or the "Company") today announced unaudited financial results for the fourth quarter ended December 31, 2025.

"2025 was a transformational year for Keenova. We completed our evolution into a purpose-driven branded therapeutics company and delivered financial results above our expectations. We also began executing on our synergy plans and remain on track to meet our targets," said Siggi Olafsson, President and Chief Executive Officer. "Our performance underscores the positive momentum in the business and our team's disciplined execution. We have now delivered two consecutive years of double-digit growth in Acthar Gel, fueled by increasing patient demand and continued uptake of SelfJect™. XIAFLEX also performed well in the fourth quarter, and today we announced a significant milestone in our hammer toe clinical program."

Mr. Olafsson added, "We have a strong foundation in place and meaningful value-creation opportunities ahead as we prepare to pursue a listing on the New York Stock Exchange in the second half of the year. Our team has embraced Keenova's mission to help patients with rare or unaddressed conditions live happier and healthier lives, and I am proud of their dedication to positioning our Company for sustainable growth and long-term success."

**Impact on 2025 Financial Results Due to Completion of Mallinckrodt-Endo Merger and Subsequent Par Health Spin-Off**

On July 31, 2025, the Company (formerly Mallinckrodt plc) completed its merger with Endo LP (formerly Endo, Inc.) ("Endo") and recorded Endo's assets and liabilities on its balance sheet at fair value. On November 10, 2025, the Company completed the separation of Par Health. Keenova is required to present Par Health's assets and liabilities, results of operations, and cash flows as discontinued operations retroactively in its financial statements.

<sup>1</sup> Repository corticotropin injection.

<sup>2</sup> Collagenase clostridium histolyticum.

<sup>3</sup> The unaudited financial results presented in this release reflect the continuing operations of Keenova Therapeutics plc. For an explanation of these measures and comparisons against prior periods, please see "Explanatory Notes and Non-GAAP Financial Measures" below.

------

**Unaudited Fourth Quarter 2025 Financial Results**

Net sales from continuing operations in the fourth quarter of 2025 were $543.0 million, an increase of $277.3 million over the same period in 2024, primarily driven by momentum in Acthar Gel and the inclusion of XIAFLEX:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acthar Gel net sales were $205.6 million, an increase of 48%, primarily driven by higher demand and continued momentum in SelfJect uptake due to commercial investments and strong execution that drove category awareness and expansion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• XIAFLEX net sales were $156.5 million.

Loss from continuing operations is expected to be between $105.0 million and $115.0 million in the fourth quarter of 2025, compared to income from continuing operations of $566.4 million in the prior year period. This change reflects costs and benefits associated with transactions that occurred in 2025 and 2024, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the fourth quarter of 2024, the Company recognized a non-recurring pre-tax gain of $754 million on the sale of its Therakos<sup>®</sup> business; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the fourth quarter of 2025, strong performance of Acthar Gel and the inclusion of XIAFLEX net sales were more than offset by $185.8 million of incremental non-cash expenses related to fair value adjustments of inventory and intangible assets, the absence of a tax expense associated with the Therakos sale recognized in the prior year period, the inclusion of Endo operating costs following the business combination, and $11.8 million of integration-related costs.

Adjusted EBITDA from continuing operations is expected to be between $210.0 million and $220.0 million, primarily driven by growth in Acthar Gel and the inclusion of XIAFLEX net sales, together with the realization of initial merger-related synergies.

**Merger Synergies Update**

Keenova realized $13 million in pre-tax merger synergies in the fourth quarter of 2025. The Company expects to realize pre-tax merger synergies of approximately $100 million in 2026 as it remains on track to achieve $150 million of annual pre-tax, run-rate synergies by the merger's three-year anniversary.

**XIAFLEX Pipeline Update**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Hammer Toe:** Proof-of-concept study enrollment was completed ahead of schedule in November 2025. Topline data demonstrated a favorable safety profile and met secondary and exploratory efficacy endpoints, enabling progression of the program into a registrational Phase 3 study. An FDA end-of-Phase 2 meeting is planned for the second quarter of 2026, with the start of the Phase 3 study expected in the fourth quarter of 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Plantar Fibromatosis:** Patient enrollment for the Phase 3 study was completed on March 5, 2026. Topline results are expected in the third quarter of 2026; regulatory submission is targeted for the fourth quarter of 2026.

**Capital Allocation Priorities**

Keenova's capital allocation priorities for 2026 include investing in organic growth to support commercial execution for Acthar Gel and XIAFLEX and fund targeted R&D to enhance the durability of the Company's portfolio.

Additionally, the Company is exploring opportunities to enhance its portfolio. This includes bolt-on acquisitions that leverage Keenova's existing capabilities to add to growth, as well as opportunistic divestitures, including a potential sale of the PERCOCET<sup>®</sup> business.

**2026 Financial Guidance**

For the full-year fiscal 2026, Keenova expects to deliver:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acthar Gel net sales growth rate in the mid-teens.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• XIAFLEX net sales growth rate in the mid- to high-single digits.<sup>4</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales of $1.94 billion to $2.00 billion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $730 million to $760 million.

The above Adjusted EBITDA guidance incorporates anticipated merger synergies to be realized in 2026. The guidance for net sales and Adjusted EBITDA does not take into account any potential acquisition or divestiture activity, including the

<sup>4</sup> Compared to aggregate XIAFLEX net sales for fiscal year 2025, which is calculated based on Endo's XIAFLEX net sales of $299.7 million for the pre-merger portion of fiscal year 2025 and Keenova's XIAFLEX net sales of $246.6 million for the post-merger portion of fiscal year 2025, for a total of $546.3 million.

------

sale of the PERCOCET business, which is expected to generate approximately $65 million in net sales and approximately $64 million in Adjusted EBITDA in full-year 2026.

The Company does not provide comparable GAAP measures for its forward-looking non-GAAP guidance or a reconciliation of such measures because the reconciling items described in the definition of Adjusted EBITDA provided below are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. The variability of such items may have a significant impact on our future GAAP results.

Please see "Non-GAAP Financial Measures" included in this release for a discussion of non-GAAP measures and reconciliation of GAAP and non-GAAP financial measures for the fourth quarter.

Please see the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to be filed with the U.S. Securities and Exchange Commission ("SEC") for additional information.

**Conference Call and Webcast**

Keenova will hold a conference call for investors today, March 31, 2026, at 8:00 a.m. Eastern Time to discuss its fourth quarter and full-year 2025 financial and operational results and outlook for 2026.

The audio webcast may be accessed through the Investor Relations section of the Company's website or through this webcast link. To access the call through a conference line, participants can register here to receive dial-in numbers and a personalized PIN to participate in the call. Participants are advised to join 10 minutes prior to the scheduled start time. A replay of the webcast will be available following the event.

**About Keenova**

Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives.

Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.

Headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. To learn more, please visit www.keenova.com.

Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

**Explanatory Notes and Non-GAAP Financial Measures**

The unaudited financial results presented in this press release reflect Keenova's continuing operations. Such unaudited financial results are subject to completion of the Company's financial closing procedures. Actual results may differ materially from these unaudited financial results.

As disclosed in the Company's Form 8-K furnished today with the SEC, the Company will file a Form 12b-25 with the SEC on April 1, 2026, which will have the effect of extending the deadline for its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "2025 Form 10-K") until April 15, 2026. The Company intends to file the 2025 Form 10-K on or prior to April 15, 2026. Please see the Company's Form 8-K for additional information.

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release includes certain financial information of the Company that is not prescribed by or prepared in accordance with GAAP. The Company utilizes these non-GAAP financial measures as supplements to financial measures determined in accordance with GAAP when evaluating operating performance and assessing the Company's capital structure, and the Company believes that these measures will be used by certain investors to evaluate operating results and financial leverage, borrowing capacity and balance sheet risk. The Company believes that presenting these non-GAAP financial measures provides useful information about performance and financial leverage across reporting periods on a consistent basis by excluding certain items, which may be favorable or unfavorable.

------

Despite the importance of these measures to management in goal-setting and performance measurement, these are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, metrics such as non-GAAP Adjusted EBITDA from continuing operations and similar metrics (unlike GAAP measures and relevant components) may differ from, and may not be comparable to, the calculation of similar measures of other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses performance.

These non-GAAP financial measures should not be viewed in isolation or as substitutes for, or superior to, financial measures calculated in accordance with GAAP. These non-GAAP financial measures should be read in conjunction with the Company's and Endo's unaudited condensed consolidated financial statements, audited financial statements, and publicly filed reports in their entirety. Reconciliations of certain of these historical adjusted financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this press release. Further information regarding non-GAAP financial measures can be found on the Company's website at www.keenova.com.

**Adjusted EBITDA**

Adjusted EBITDA represents net income or loss prepared in accordance with GAAP and adjusted for certain items that management believes are not reflective of the operational performance of the business. Adjustments to GAAP amounts include, as applicable to each measure, interest expense, net; income tax expense; depreciation and amortization; combination, integration, and other related expenses; restructuring charges, net; liabilities management and separation costs; gains/losses on debt extinguishment; gains/losses on divestitures; fresh-start inventory-related expenses; business combination inventory-related expense; share-based compensation; and other items identified by the Company.

**Adjusted EBITDA from Continuing Operations**

Adjusted EBITDA from continuing operations represents Adjusted EBITDA (as defined above) and as adjusted for income (loss) from discontinued operations.

**Forward Looking Statements**

Statements in this Press Release that are not strictly historical, including statements regarding the future financial condition and operating results of the Company, expected product launches, legal, economic, business, competitive and/or regulatory factors affecting Keenova's businesses and any other statements regarding events or developments Keenova believes or anticipates will or may occur in the future, may be "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. Forward-looking statements can be identified by the use of forward-looking terminology such as the words "believe," "expect," "plan," "intend," "project," "anticipate," "approximately," "estimate," "predict," "potential," "continue," "may," "could," "should," "will" or the negative of these terms or similar expressions.

There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: the risk that the completion and filing of the Company's 2025 Form 10-K will take longer than expected and any related consequences thereof, including triggering an event of default with respect to the Company's credit agreement for its revolving credit facility and term loan facility and the indenture related to certain senior secured notes, which could result in substantially all of the indebtedness under such agreements becoming immediately due and payable if the Company does not file within the grace periods defined in such agreements; the expected benefits and synergies of the merger with Endo may not be fully realized in a timely manner, or at all; the Company's increased indebtedness as a result of the merger with Endo and significant transaction costs related to the merger with Endo; the expected growth opportunities, profit improvements, cost savings and other benefits as a result of the spin-off of Par Health may not be fully realized in a timely manner, or at all; loss of the benefits of services provided by Par Health or certain of its subsidiaries; risks associated with being a smaller, less diversified company as a result of the spin-off of Par Health; unanticipated costs, litigation and/or regulatory inquiries and investigations, including as a result of the merger with Endo or the spin-off of Par Health; potential changes in the estimated fair value of the net assets acquired in the merger with Endo; potential changes in the Company's business strategy and performance; exposure to global economic conditions and market uncertainty; governmental investigations and inquiries, regulatory actions, and lawsuits, in each case related to the Company or its officers; the Company's contractual and court-ordered compliance obligations that, if violated, could result in penalties; matters related to Acthar® Gel (repository corticotropin injection), including the settlement with governmental parties to resolve certain disputes and compliance with and restrictions under the related corporate integrity agreement; the ability to maintain relationships with the Company's suppliers, customers, employees and other third parties; scrutiny from governments, legislative bodies and enforcement agencies related to sales, marketing and pricing practices; pricing pressure on certain of the Company's products due to legal changes or changes in insurers' or other payers' reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; the reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers; complex reporting and payment

------

obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; changes in or failure to comply with relevant laws and regulations; any undesirable side effects caused by the Company's approved and investigational products, which could limit their commercial profile or result in other negative consequences; the Company's and its partners' ability to successfully develop, commercialize or launch new products or expand commercial opportunities of existing products, including Acthar Gel SelfJect, the INOmax® Evolve DS delivery system, and XIAFLEX® (collagenase clostridium histolyticum); the Company's ability to successfully pursue additional indications for XIAFLEX, including the timing and outcome of clinical results and regulatory submissions; the Company's ability to successfully identify or discover additional products or product candidates; the Company's ability to navigate price fluctuations and pressures, including the ability to achieve anticipated benefits of price increases of its products; competition; the Company's and its partners' ability to protect intellectual property rights; limited clinical trial data for Acthar Gel; the timing, expense and uncertainty associated with clinical studies and related regulatory processes; product liability losses and other litigation liability; material health, safety and environmental laws and related liabilities; business development activities or other strategic transactions; attraction and retention of qualified personnel in key fields; the effectiveness of information technology infrastructure, including risks of external attacks or failures; customer concentration; the Company's reliance on certain individual products that are material to its financial performance; complex manufacturing processes; reliance on third-party manufacturers and supply chain providers and related market disruptions; conducting business internationally; new or increased tariffs and evolving trade relations and changes in trade and taxation policy; the Company's significant levels of intangible assets and related impairment testing; natural disasters or other catastrophic events; the Company's substantial indebtedness and settlement obligation, its ability to generate sufficient cash to reduce its indebtedness and its potential need and ability to incur further indebtedness; restrictions contained in the agreements governing the Company's indebtedness and settlement obligation on the Company's operations, future financings and use of proceeds; the Company's variable rate indebtedness; the Company's tax treatment by the Internal Revenue Service under Section 7874 and Section 382 of the Internal Revenue Code of 1986, as amended; future changes to applicable tax laws or the impact of disputes with governmental tax authorities; the impact of Irish laws; the comparability of the Company's financial results to historical financial statements in light of its emergence from Chapter 11 bankruptcy proceedings in 2023, the divestiture of the Therakos business, the merger with Endo and spin-off of Par Health.

The "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 27, 2024, its Quarterly Report on Form 10-Q for the quarterly period ended March 28, 2025, its Quarterly Report for the quarterly period ended June 27, 2025, its Quarterly Report for the quarterly period ended September 26, 2025, its Registration Statement on Form S-4, as amended, filed with the SEC, and other filings with the SEC, all of which are on file with the SEC and available from the SEC's website (www.sec.gov) and the Company's website (www.keenova.com), identify and describe in more detail the risks and uncertainties to which the Company's businesses are subject. There may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business. The forward-looking statements made herein speak only as of the date hereof and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. Given these uncertainties, one should not put undue reliance on any forward-looking statements.

**No Offer of Securities**

The Company's potential NYSE listing in the second half of 2026 is subject to approval by Keenova's Board of Directors and other considerations and conditions. The Company expects to conduct a public offering of Keenova's ordinary shares to facilitate the listing at that time, and no assurance can be given as to whether or when such transaction will occur or its impact.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any such offering would be made pursuant to a registration statement to be filed with the SEC. The price and number of the ordinary shares to be sold in any such offering have not yet been determined. The timing of any such offering would be subject to market and other conditions and the completion of the SEC's review process. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

------

**CONTACTS**

**Investors:**

investor.relations@keenova.com

**Media:**

media.relations@keenova.com

or

Aura Reinhard / Catherine Simon

Joele Frank, Wilkinson Brimmer Katcher

212-355-4449

------

---

| | | | |
|:---|:---|:---|:---|
| **KEENOVA THERAPEUTICS PLC** | **KEENOVA THERAPEUTICS PLC** | **KEENOVA THERAPEUTICS PLC** | **KEENOVA THERAPEUTICS PLC** |
| **SELECT PRODUCT LINE NET SALES** | **SELECT PRODUCT LINE NET SALES** | **SELECT PRODUCT LINE NET SALES** | **SELECT PRODUCT LINE NET SALES** |
| *(unaudited, dollars in millions)* | *(unaudited, dollars in millions)* | *(unaudited, dollars in millions)* | *(unaudited, dollars in millions)* |
|  |  |  | **Change** |
|  | **4Q25** | **4Q24** | $**%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acthar Gel | $205.6 | $138.9 | 48% |
| &nbsp;&nbsp;&nbsp;&nbsp;Xiaflex | 156.5 |  | —% |
| &nbsp;&nbsp;&nbsp;&nbsp;INOmax | 61.5 | 60.8 | 1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Therakos |  | 48.6 | NM |
| &nbsp;&nbsp;&nbsp;&nbsp;Amitiza | 14.4 | 9.5 | 52% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Products | 81.2 | 7.9 | NM |
| &nbsp;&nbsp;&nbsp;&nbsp;License Revenues | 23.9 |  | —% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $543.0 | $265.7 | 104% |

---

________

NM indicates that the percentage change is not meaningful or is greater than 100%.

---

| | | |
|:---|:---|:---|
| **KEENOVA THERAPEUTICS PLC** | **KEENOVA THERAPEUTICS PLC** | **KEENOVA THERAPEUTICS PLC** |
| **CONSOLIDATED ADJUSTED EBITDA** | **CONSOLIDATED ADJUSTED EBITDA** | **CONSOLIDATED ADJUSTED EBITDA** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **Estimated 4Q25** | **4Q24** |
| Net (loss) income | $(173.4) | $612.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss (income) from discontinued operations | 63.4 | (46.4) |
| (Loss) income from continuing operations before taxes<sup>(1)</sup> | (110.0) | 566.4 |
| Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 48.9 | 45.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 0.3 | 116.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 5.2 | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 56.5 | 10.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Combination, integration, and other related expenses | 11.8 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Liabilities management and separation costs | (1.0) | 11.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on debt extinguishment, net | 0.1 | 19.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on divestiture |  | (754.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fresh-start inventory-related expense | 54.5 | 39.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Business combination inventory-related expenses | 125.3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 9.9 | 3.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | 11.3 | (0.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in derivative asset and liabilities fair value | 0.8 | (13.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized (gain) loss on equity investment | (0.9) | 18.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 2.3 | 2.0 |
| **Adjusted EBITDA from continuing operations**<sup>(1)</sup> | $**215.0** | $**67.9** |

---

________

(1) Loss from continuing operations before taxes reflects the midpoint of the estimated range of $105 million to $115 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA from continuing operations reflects the midpoint of the estimated range of $210 million to $220 million.

## Exhibit 99.2

**Exhibit 99.2**

**KEENOVA THERAPEUTICS PLC**

The following unaudited non-GAAP pro forma combined net sales and adjusted EBITDA are derived from the historical consolidated financial statements of Keenova Therapeutics plc (formerly known as Mallinckrodt plc, "Keenova" or the "Company"), Endo LP (formerly known as Endo, Inc., "Endo") and Endo International plc ("Endo's Predecessor"). Such unaudited financial information is subject to the completion of the Company's financial closing procedures. Actual results may differ materially from this unaudited financial information. This supplemental information contains "non-GAAP" financial measures under applicable Securities and Exchange Commission ("SEC") rules and regulations. See "Presentation of Historical Financial Information and Non-GAAP Financial Measures" below for additional information.

The unaudited non-GAAP pro forma combined net sales and adjusted EBITDA primarily reflect the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Therakos® Divestiture – On November 29, 2024, the Company completed the divestiture of its Therakos business ("Therakos Divestiture").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Mallinckrodt and Endo Business Combination – On July 31, 2025, the Company acquired Endo with Endo continuing as a wholly-owned subsidiary of the Company (such merger, the "Business Combination").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Par Health Separation – On November 10, 2025, the Company completed the separation of the combined businesses of the historical "Specialty Generics" reportable segment of Mallinckrodt and the historical "Generic Pharmaceuticals" and "Sterile Injectables" reportable segments of Endo into an independent, private company named Par Health (the "Separation").

The following tables summarize non-GAAP pro forma combined net sales by select product line for the periods presented (components may include immaterial rounding).

---

| | | | |
|:---|:---|:---|:---|
| **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **4Q25** <sup>(1)</sup> | **Other** <sup>(2)</sup> | **Pro Forma 4Q25** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acthar Gel | $205.6 | $— | $205.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Xiaflex | 156.5 |  | 156.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;INOmax | 61.5 |  | 61.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amitiza | 14.4 |  | 14.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Products | 81.2 | (1.1) | 80.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;License Revenues | 23.9 |  | 23.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $543.0 | $(1.1) | $541.9 |

---

(1)4Q25 Keenova Net Sales

(2)Removes Endocet (a discontinued Gx product) net sales included in "4Q25"

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **4Q24** <sup>(1)</sup> | **Endo Pre-Merger** <sup>(2)</sup> | **Remove Therakos** <sup>(3)</sup> | **Pro Forma 4Q24** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acthar Gel | $138.9 | $— | $— | $138.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Xiaflex |  | 147.9 |  | 147.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;INOmax | 60.8 |  |  | 60.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Therakos | 48.6 |  | (48.6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amitiza | 9.5 |  |  | 9.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Products | 7.9 | 91.1 |  | 99.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;License Revenues |  | 7.9 |  | 7.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $265.7 | $247.0 | $(48.6) | $464.0 |

---

(1)Historical net sales of Keenova Brands

(2)Addition of Endo Brands Net Sales for the quarter as derived from Endo accounting records

(3)Removal of Therakos due to divestiture in 2024

---

| | | | | |
|:---|:---|:---|:---|:---|
| **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **FY25** <sup>(1)</sup> | **Endo Pre-Merger** <sup>(2)</sup> | **Other** <sup>(3)</sup> | **Pro Forma FY25** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acthar Gel | $677.5 | $— | $— | $677.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Xiaflex | 246.6 | 299.7 |  | 546.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;INOmax | 244.8 |  |  | 244.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amitiza | 70.6 |  |  | 70.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Products | 160.6 | 188.3 | (1.8) | 347.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;License Revenues | 30.6 | 13.6 |  | 44.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $1430.6 | $501.6 | $(1.8) | $1930.4 |

---

(1)FY25 Keenova Net Sales

(2)Addition of Endo Brands Net Sales for the pre-merger period January 1 to July 31, 2025, as derived from Endo accounting records

(3)Removes Endocet (a discontinued Gx product) net sales included in "FY25"

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** | **NON-GAAP PRO FORMA COMBINED SELECT PRODUCT LINE NET SALES** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **FY24** <sup>(1)</sup> | **Endo Pre-Merger** <sup>(2)</sup> | **Remove Therakos** <sup>(3)</sup> | **Pro Forma FY24** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acthar Gel | $485.7 | $— | $— | $485.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Xiaflex |  | 515.6 |  | 515.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;INOmax | 261.4 |  |  | 261.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Therakos | 241.6 |  | (241.6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amitiza | 62.9 |  |  | 62.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Products | 31.8 | 343.0 |  | 374.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;License Revenues |  | 31.3 |  | 31.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $1083.5 | $889.9 | $(241.6) | $1731.8 |

---

(1)Historical net sales of Keenova Brands

(2)Addition of Endo Brands net sales for the combined pre-merger period January 1, 2024 to April 23, 2024 (Predecessor) and January 1, 2024 to December 31, 2024 (Successor), as derived from Endo accounting records

(3)Removal of Therakos due to divestiture in 2024

The following tables summarize non-GAAP pro forma combined adjusted EBITDA for the periods presented (components may include immaterial rounding).

---

| | | | |
|:---|:---|:---|:---|
| **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **Estimated 4Q25** <sup>(1)</sup> | **Other** <sup>(2)</sup> | **Pro Forma 4Q25** |
| Net loss | $(173.4) | $(0.3) | $(173.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss from discontinued operations | 63.4 |  | 63.4 |
| Loss from continuing operations before taxes <sup>(3)</sup> | (110.0) | (0.3) | (110.3) |
| Adjustments: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 48.9 |  | 48.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 0.3 |  | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 5.2 |  | 5.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 56.5 |  | 56.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Combination, integration, and other related expenses | 11.8 |  | 11.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liabilities management and separation costs | (1.0) |  | (1.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on debt extinguishment, net | 0.1 |  | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fresh-start inventory-related expense | 54.5 |  | 54.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Business combination inventory-related expenses | 125.3 |  | 125.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 9.9 |  | 9.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | 11.3 |  | 11.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in derivative asset and liabilities fair value | 0.8 |  | 0.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on equity investment | (0.9) |  | (0.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 2.3 |  | 2.3 |
| **Adjusted EBITDA from continuing operations** <sup>(3)</sup> | $**215.0** | $**(0.3)** | $**214.7** |

---

(1)4Q25 Keenova results; Loss from continuing operations and Adjusted EBITDA from continuing operations reflect the mid-point of the estimated ranges described below

(2)Removes Endocet (a discontinued Gx product) results included in "FY25"

------

(3)Loss from continuing operations before taxes reflects the midpoint of the estimated range of $105 million to $115 million.<br>Adjusted EBITDA from continuing operations reflects the midpoint of the estimated range of $210 million to $220 million

---

| | | | | |
|:---|:---|:---|:---|:---|
| **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **4Q24** <sup>(1)</sup> | **Endo Pre-Merger** <sup>(2)</sup> | **Therakos** <sup>(3)</sup> | **Pro Forma 4Q24** |
| Net Income (loss) | $612.8 | $(78.5) | $(27.9) | $506.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (income) loss from discontinued operations | (46.4) | 9.7 |  | (36.7) |
| Income (loss) from continuing operations before taxes | 566.4 | (68.8) | (27.9) | 469.7 |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 45.1 | 56.9 |  | 102.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense (benefit) | 116.4 | (44.2) |  | 72.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 2.1 | 6.3 |  | 8.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 10.7 | 46.8 |  | 57.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Combination, integration, and other related expenses |  | 4.8 |  | 4.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liabilities management and separation costs | 11.7 |  |  | 11.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on debt extinguishment, net | 19.8 | (1.1) |  | 18.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on divestiture | (754.4) | (0.4) |  | (754.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fresh-start inventory-related expense (benefit) | 39.7 | 118.1 | (2.1) | 155.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 3.3 | 2.7 |  | 6.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | (0.4) | 0.3 |  | (0.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in derivative asset and liabilities fair value | (13.4) |  |  | (13.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on equity investment | 18.8 |  |  | 18.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 2.0 | 0.8 | 1.9 | 4.7 |
| **Adjusted EBITDA from continuing operations** | $**67.9** | $**122.2** | $**(28.1)** | $**162.0** |

---

(1)Historical results of Keenova Brands business

(2)Addition of Endo Brands and Corporate results for the quarter as derived from Endo accounting records

(3)Removal of Therakos due to divestiture in 2024

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **Estimated FY25** <sup>(1)</sup> | **Endo Pre-Merger** <sup>(2)</sup> | **Other** <sup>(3)</sup> | **Pro Forma FY25** |
| Net (loss) income | $(492.0) | $(375.9) | $(0.6) | $(868.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss from discontinued operations | 32.0 | 26.2 |  | 58.2 |
| Income (loss) from continuing operations before taxes <sup>(4)</sup> | (460.0) | (349.7) | (0.6) | (810.2) |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 149.2 | 124.3 |  | 273.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) expense | (24.0) | 117.9 |  | 94.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 15.1 | 6.2 |  | 21.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 115.5 | 108.7 |  | 224.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Combination, integration, and other related expenses | 141.2 | 66.0 |  | 207.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring benefits, net | (2.2) |  |  | (2.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Liabilities management and separation costs | 0.1 |  |  | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on debt extinguishment, net | (15.8) |  |  | (15.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on divestiture | 5.9 |  |  | 5.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fresh-start inventory-related expense | 183.8 | 140.7 |  | 324.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Business combination inventory-related expenses | 209.0 |  |  | 209.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 43.7 | 5.0 |  | 48.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | 14.3 | 1.3 |  | 15.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in derivative asset and liabilities fair value | 5.2 |  |  | 5.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on equity investment | 1.7 |  |  | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 2.3 | 3.5 |  | 5.8 |
| **Adjusted EBITDA from continuing operations** <sup>(4)</sup> | $**385.0** | $**224.1** | $**(0.6)** | $**608.5** |

---

(1)FY25 Keenova results; Loss from continuing operations and Adjusted EBITDA from continuing operations reflect the mid-point of the estimated ranges described below

(2)Addition of Endo Brands and Corporate results for the pre-merger period January 1 to July 31, 2025, as derived from Endo accounting records

(3)Removes Endocet (a discontinued Gx product) results included in "FY25"

(4)Income (loss) from continuing operations before taxes for FY25 reflects the midpoint of the estimated range of $455 million to $465 million<br>Adjusted EBITDA from continuing operations for FY25 reflects the midpoint of the estimated range of $380 million to $390 million

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** | **NON-GAAP PRO FORMA COMBINED ADJUSTED EBITDA** |
| *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* | *(unaudited, in millions)* |
|  | **FY24** <sup>(1)</sup> | **Endo Pre-Merger** <sup>(2)</sup> | **Therakos** <sup>(3)</sup> | **Pro Forma FY24** |
| Net (loss) income | $477.9 | $5679.9 | $(66.7) | $6091.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss from discontinued operations | (133.6) | (144.8) |  | (278.4) |
| Income (loss) from continuing operations before taxes <sup>(4)</sup> | 344.4 | 5535.1 | (66.7) | 5812.8 |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 204.7 | 164.8 |  | 369.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) expense | 113.2 | (72.5) |  | 40.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 7.3 | 20.5 |  | 27.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 66.2 | 172.2 | (16.3) | 222.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Combination, integration, and other related expenses |  | 34.2 |  | 34.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges, net | 10.5 |  |  | 10.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liabilities management and separation costs | 43.9 |  |  | 43.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on debt extinguishment, net | 19.8 | (0.5) |  | 19.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on divestiture | (754.4) |  |  | (754.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fresh-start inventory-related expense | 250.9 | 382.5 | (66.3) | 567.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 6.7 | 2.7 |  | 9.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | 2.8 | 0.4 |  | 3.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in derivative asset and liabilities fair value | (7.4) |  |  | (7.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on equity investment | 17.4 |  |  | 17.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reorganization items, net |  | (5820.2) |  | (5820.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (2.4) | 0.2 | 10.0 | 7.7 |
| **Adjusted EBITDA from continuing operations** | $**323.4** | $**419.5** | $**(139.3)** | $**603.6** |

---

(1)Historical results of Keenova Brands business

(2)Addition of Endo Brands and Corporate results for the combined pre-merger period January 1, 2024 to April 23, 2024 (Predecessor) and January 1, 2024 to December 31, 2024 (Successor), as derived from Endo accounting records

(3)Removal of Therakos due to divestiture in 2024

**<u>Presentation of Historical Financial Information and Non-GAAP Financial Measures</u>**

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this supplemental financial information includes certain financial information of the Company that is not prescribed by or prepared in accordance with GAAP. The Company utilizes these non-GAAP financial measures as supplements to financial measures determined in accordance with GAAP when evaluating operating performance and assessing the Company's capital structure, and the Company believes that these measures will be used by certain investors to evaluate operating results and financial leverage, borrowing capacity and balance sheet risk. The Company believes that presenting these non-GAAP financial measures provides useful information about performance and financial leverage across reporting periods on a consistent basis by excluding certain items, which may be favorable or unfavorable.

For comparisons against prior periods, such prior period information was prepared on a pro forma basis the Mallinckrodt-Endo merger and the separation of Par Health had each occurred at the beginning of the respective periods presented. Pro forma combined results for 2024 also exclude the results of the Company's former Therakos business, which was sold in 2024, and pro forma combined results for 2024 and 2025 also exclude Endo's International Pharmaceuticals business, which was sold in 2025. The pro forma prior period information was prepared for illustrative and informational purposes only. Such pro forma financial information has not been prepared and presented in accordance with the requirements of Article 11 of Regulation S-X or Accounting Standards Codification 805, Business Combinations.

Despite the importance of these measures to management in goal-setting and performance measurement, these are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their

------

usefulness to investors. Because of the non-standardized definitions, metrics such as non-GAAP Adjusted EBITDA from continuing operations and similar metrics (unlike GAAP measures and relevant components) may differ from, and may not be comparable to, the calculation of similar measures of other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses performance.

These non-GAAP financial measures should not be viewed in isolation or as substitutes for, or superior to, financial measures calculated in accordance with GAAP. These non-GAAP financial measures should be read in conjunction with the Company's and Endo's unaudited condensed consolidated financial statements, audited financial statements, and publicly filed reports in their entirety. Further information regarding non-GAAP financial measures can be found on the Company's website at www.keenova.com.

***Adjusted EBITDA from continuing operations***

Adjusted EBITDA from continuing operations represents net income or loss prepared in accordance with GAAP and adjusted for certain items that management believes are not reflective of the operational performance of the business. Adjustments to GAAP amounts include, as applicable to each measure, income (loss) from discontinued operations, interest expense, net; income tax expense; depreciation and amortization; combination, integration, and other related expenses; restructuring charges, net; liabilities management and separation costs; gains/losses on debt extinguishment; gains/losses on divestitures; fresh-start inventory-related expenses; business combination inventory-related expense; share-based compensation; and other items identified by the Company.

<br>